CORDIS
EU research results

CORDIS

English EN
ISOTOPIC LABELING FOR DRUG INNOVATION

ISOTOPIC LABELING FOR DRUG INNOVATION

Objective

Excessive attrition rates during clinical trials dramatically impact on Drug Discovery and Development (DDD). Absorption, Distribution, Metabolism and Excretion studies carried out on larger series of drug candidates at an earlier stage of the DDD timeline and evaluation of drug efficacy through better assessment of pharmacokinetic/pharmacodynamic relationships, target engagement and receptor occupancy are critically important approaches for de-risking drug innovation since they facilitate early identification of the candidates that display the best in vivo profile. When successfully implemented, this strategy can accelerate the discovery of new therapeutic solutions to existing and emerging diseases, and enhance European pharmaceutical innovation. For implementation, large sets of isotopically-labeled molecules are required and consequently, a huge revival of labeling techniques is urgently needed. Another crucial issue is the scarcity of expert radiochemists in Europe and the lack of first class training programs in this inter-disciplinary field merging chemistry, radiochemistry and medicinal chemistry. The aims of ISOTOPICS are: i) to train the next generation of European chemists with expertise in isotopic labeling and advanced medicinal chemistry through a first-class taught and research training program combined with a highly interactive secondments plan; ii) to develop innovative and general isotopic labeling chemistry and radiochemistry to streamline the synthesis of labeled small-molecule drugs and biologics; iii) to work closely with the European pharmaceutical industry to apply the new labeling methods to drugs currently in development in order to provide solutions to the most pressing problems in drug innovation. This highly interdisciplinary project is expected to have a profound beneficial impact on drug innovation in Europe by providing novel efficient techniques and new experts in the fields of labeling and medicinal chemistries.

Coordinator

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

Address

Rue Leblanc 25
75015 Paris 15

France

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 051 502,40

Participants (8)

Sort alphabetically

Sort by EU Contribution

Expand all

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 1 093 151,52

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 527 318,64

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 262 875,60

UNIVERSITE DE LIEGE

Belgium

EU Contribution

€ 250 560

UCB PHARMA SA

Belgium

ASTRAZENECA AB

Sweden

EU Contribution

€ 263 659,32

SANOFI-AVENTIS DEUTSCHLAND GMBH

Germany

EU Contribution

€ 249 216,48

UCB BIOPHARMA SPRL

Belgium

EU Contribution

€ 250 560

Partners (4)

Sort alphabetically

Expand all

UNIVERSITE PARIS-SUD

INSTN

LERMIT

Société de Chimie Thérapeutique

Project information

Grant agreement ID: 675071

Status

Ongoing project

  • Start date

    1 January 2016

  • End date

    31 December 2019

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 948 843,96

  • EU contribution

    € 3 948 843,96

Coordinated by:

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

France